The response has been better than anticipated. As of the end of the first day on the evening of 13 July, Rossari Biotech IPO was 60% subscribed. This spurt in demand was largely driven by the robust anchor investments received earlier by the company. Out of the total 81.73 lakh shares on issue, subscriptions to the tune of 49.30 lakh shares on Day-1 itself.

QIB portion was subscribed 41%, non-institutional portion 11% while the retail portion was subscribed a robust 92% at the end of Day-1. Normally, applications in the QIB and the non-institutional category come only on the last day, so the issue could get a very good oversubscription by 15 July. This is the first IPO in 4 months after SBI Cards in March.